Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 23,383 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 23,383 shares of Genelux stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $2.70, for a total transaction of $63,134.10. Following the sale, the insider now owns 716,438 shares in the company, valued at approximately $1,934,382.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, September 11th, Aladar Szalay sold 31,376 shares of Genelux stock. The shares were sold at an average price of $2.62, for a total transaction of $82,205.12.
• On Tuesday, September 3rd, Aladar Szalay sold 42,818 shares of Genelux stock. The stock was sold at an average price of $2.09, for a total transaction of $89,489.62.
• On Thursday, August 29th, Aladar Szalay sold 107,045 shares of Genelux stock. The shares were sold at an average price of $1.98, for a total value of $211,949.10.
• On Tuesday, August 27th, Aladar Szalay sold 51,630 shares of Genelux stock. The stock was sold at an average price of $2.11, for a total value of $108,939.30.
• On Friday, August 23rd, Aladar Szalay sold 40,000 shares of Genelux stock. The shares were sold at an average price of $2.29, for a total value of $91,600.00.

Genelux Stock Performance

NASDAQ GNLX opened at $2.60 on Thursday. The company has a market cap of $89.32 million, a P/E ratio of -2.68 and a beta of -1.55. The business’s 50 day moving average price is $2.19 and its 200-day moving average price is $3.48. Genelux Co. has a fifty-two week low of $1.60 and a fifty-two week high of $30.44.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, equities analysts predict that Genelux Co. will post -0.9 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Roth Capital raised Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Genelux in a research note on Thursday, August 15th. Roth Mkm started coverage on shares of Genelux in a research note on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Benchmark reduced their target price on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating on the stock in a report on Friday, May 31st. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $26.75.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GNLX. Woodward Diversified Capital LLC boosted its holdings in Genelux by 0.3% during the 1st quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after acquiring an additional 3,687 shares during the period. Vanguard Group Inc. lifted its position in shares of Genelux by 2.4% during the first quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock worth $6,578,000 after purchasing an additional 24,220 shares during the last quarter. Armistice Capital LLC bought a new stake in shares of Genelux during the second quarter worth $1,755,000. Highbridge Capital Management LLC purchased a new stake in shares of Genelux during the second quarter valued at $1,231,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Genelux in the second quarter worth about $195,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.